Truffle Capital, an investor in Pharnext, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
- Pharnext is a Paris-based biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases. The company’s proprietary «drug repositioning » approach consists in identifying the common drug molecular targets between unrelated diseases, testing existing drugs on newly identified indications, and developing drug combinations for such new indications, such as orphan diseases by. Founded in 2007 by an internationally renowned team led by Professor Daniel Cohen, responsible for many discoveries in medical genetics, Pharnext is focusing on severe neurodegenerative disease in general, and peripheral neuropathies in particular (Charcot Marie Tooth disease), which affect hundreds of millions of people worldwide.
- Following a seed investment of €3.5 million by founding and sole investor Truffle Capital in December 2007 and an Oseo grant of €3.4 million, Pharnext plans to broaden its strategy to include other handicapping conditions, such as Alzheimer's disease.
Truffle board member: Dr. Philippe Pouletty